ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data

ADC Therapeutics shares plunged 53% after-hours as investors reacted negatively to safety concerns in a phase III DLBCL study of Zynlonta, even though the trial met its primary efficacy endpoint. The selloff suggests the safety profile may materially affect commercial prospects and market confidence. The move is likely to pressure the stock significantly and could weigh on biotech sentiment around late-stage oncology trials.

Analysis

ADC Therapeutics shares plunged 53% after-hours as investors reacted negatively to safety concerns in a phase III DLBCL study of Zynlonta, even though the trial met its primary efficacy endpoint. The selloff suggests the safety profile may materially affect commercial prospects and market confidence. The move is likely to pressure the stock significantly and could weigh on biotech sentiment around late-stage oncology trials.